All Stories

  1. Hepatitis E virus genome plasticity: a marker of chronicity and therapy failure?
  2. Viral entry defines the hepatitis E virus species barrier in murine hepatocytes
  3. Yellow fever vaccine propagation in primary human hepatocytes triggers antiviral and cytolytic responses
  4. From Discovery to Therapy: The Role of HSPB1 in HBV Persistence
  5. Seroprevalence of segmented flavi-like Alongshan virus in horses
  6. From zoonotic spillover to endemicity: the broad determinants of human coronavirus tropism
  7. Mycophenolic acid treatment drives the emergence of novel SARS-CoV-2 variants
  8. Adapted hepatitis C virus clone infects innate immunity-deficient mouse hepatocytes with minimal human HCV entry factors
  9. Differential efficacy of first licensed western vaccines protecting without immunopathogenesis Wuhan-1-challenged hamsters from severe COVID-19
  10. The glutamate receptor antagonist ifenprodil inhibits hepatitis E virus infection
  11. MicroRNAs modulate SARS‐CoV‐2 infection of primary human hepatocytes by regulating the entry factors ACE2 and TMPRSS2
  12. Inactivation of yellow fever virus by WHO-recommended hand rub formulations and surface disinfectants
  13. Host determinants and responses underlying SARS-CoV-2 liver tropism
  14. TMPRSS2-mediated SARS-CoV-2 uptake boosts innate immune activation, enhances cytopathology, and drives convergent virus evolution
  15. Targeting cellular cathepsins inhibits hepatitis E virus entry
  16. Unraveling the dynamics of hepatitis C virus adaptive mutations and their impact on antiviral responses in primary human hepatocytes
  17. Repurposing screen identifies novel candidates for broad-spectrum coronavirus antivirals and druggable host targets
  18. Spatiotemporal analysis of SARS-CoV-2 infection reveals an expansive wave of monocyte-derived macrophages associated with vascular damage and virus clearance in hamster lungs
  19. Productive infection of primary human hepatocytes with SARS-CoV-2 induces antiviral and proinflammatory responses
  20. Mouse Liver-Expressed Shiftless Is an Evolutionarily Conserved Antiviral Effector Restricting Human and Murine Hepaciviruses
  21. Spatiotemporal analysis of SARS-CoV-2 infection reveals an expansive wave of monocyte-derived macrophages associated with vascular damage and virus clearance in hamster lungs
  22. SARS-CoV-2 entry route impacts a range of downstream viral and cellular processes
  23. Vaccine-associated enhanced respiratory pathology in COVID-19 hamsters after TH2-biased immunization
  24. The Human Liver-Expressed Lectin CD302 Restricts Hepatitis C Virus Infection
  25. Intra-host analysis of hepaciviral glycoprotein evolution reveals signatures associated with viral persistence and clearance
  26. In contrast to TH2-biased approaches, TH1 COVID-19 vaccines protect Syrian hamsters from severe disease in the absence of dexamethasone-treatable vaccine-associated enhanced respiratory pathology
  27. Generation of hiPSC-derived low threshold mechanoreceptors containing axonal termini resembling bulbous sensory nerve endings and expressing Piezo1 and Piezo2
  28. Strategies to Inhibit Hepatitis B Virus at the Transcript Level
  29. Initial Hepatitis C Virus Infection of Adult Hepatocytes Triggers a Temporally Structured Transcriptional Program Containing Diverse Pro- and Antiviral Elements
  30. Single-cell analysis of arthritogenic alphavirus-infected human synovial fibroblasts links low abundance of viral RNA to induction of innate immunity and arthralgia-associated gene expression
  31. Liver-expressed Cd302 and Cr1l limit hepatitis C virus cross-species transmission to mice
  32. C19orf66 is an interferon-induced inhibitor of HCV replication that restricts formation of the viral replication organelle
  33. Efficient acute and chronic infection of stem cell-derived hepatocytes by hepatitis C virus
  34. Yellow Fever: Integrating Current Knowledge with Technological Innovations to Identify Strategies for Controlling a Re-Emerging Virus
  35. Identification of Keratin 23 as a Hepatitis C Virus-Induced Host Factor in the Human Liver
  36. A central hydrophobic E1 region controls the pH range of hepatitis C virus membrane fusion and susceptibility to fusion inhibitors
  37. Functional and immunogenic characterization of diverse HCV glycoprotein E2 variants
  38. Hepatitis C Virus
  39. Immunization with a synthetic consensus hepatitis C virus E2 glycoprotein ectodomain elicits virus-neutralizing antibodies
  40. Molecular characteristics and successful management of a respiratory syncytial virus outbreak among pediatric patients with hemato-oncological disease
  41. Hepatitis C Virus Strain-Dependent Usage of Apolipoprotein E Modulates Assembly Efficiency and Specific Infectivity of Secreted Virions
  42. Immune protection against reinfection with nonprimate hepacivirus
  43. Exacerbation of hepatitis E virus infection during anti-TNFα treatment
  44. Tracking HCV protease population diversity during transmission and susceptibility of founder populations to antiviral therapy
  45. Hepacivirus NS3/4A Proteases Interfere with MAVS Signaling in both Their Cognate Animal Hosts and Humans: Implications for Zoonotic Transmission
  46. Mutagenic Effects of Ribavirin on Hepatitis E Virus—Viral Extinction versus Selection of Fitness-Enhancing Mutations
  47. Vertical transmission of hepatitis C virus-like non-primate hepacivirus in horses
  48. Hepatitis E Virus (HEV) ORF2 Antigen Levels Differentiate Between Acute and Chronic HEV Infection
  49. In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome
  50. Ion Channel Function and Cross-Species Determinants in Viral Assembly of Nonprimate Hepacivirus p7
  51. A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance
  52. Flunarizine prevents hepatitis C virus membrane fusion in a genotype‐dependent manner by targeting the potential fusion peptide within E1
  53. Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice
  54. Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine Design
  55. Clinical course of infection and viral tissue tropism of hepatitis C virus–like nonprimate hepaciviruses in horses
  56. Development of a high-throughput pyrosequencing assay for monitoring temporal evolution and resistance associated variant emergence in the Hepatitis C virus protease coding-region
  57. Incorporation of primary patient-derived glycoproteins into authentic infectious hepatitis C virus particles
  58. Natural reservoirs for homologs of hepatitis C virus
  59. Recombinant Human L-Ficolin Directly Neutralizes Hepatitis C Virus Entry
  60. Use of short tandem repeat fingerprinting to validate sample origins in hepatitis C virus molecular epidemiology studies
  61. Cell entry, efficient RNA replication, and production of infectious hepatitis C virus progeny in mouse liver-derived cells
  62. Analysis of Serine Codon Conservation Reveals Diverse Phenotypic Constraints on Hepatitis C Virus Glycoprotein Evolution
  63. Mannan binding lectin-associated serine protease 1 is induced by hepatitis C virus infection and activates human hepatic stellate cells
  64. Characterization of Hepatitis C Virus Intra- and Intergenotypic Chimeras Reveals a Role of the Glycoproteins in Virus Envelopment
  65. An Alpaca Nanobody Inhibits Hepatitis C Virus Entry And Cell-To-Cell Transmission
  66. Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells
  67. Hepatitis C Virus Envelope Glycoprotein Fitness Defines Virus Population Composition following Transmission to a New Host
  68. Naturally Occurring Antibodies That Recognize Linear Epitopes in the Amino Terminus of the Hepatitis C Virus E2 Protein Confer Noninterfering, Additive Neutralization
  69. Intercompartmental Recombination of HIV-1 Contributes to env Intrahost Diversity and Modulates Viral Tropism and Sensitivity to Entry Inhibitors
  70. Hepatitis C Patient-Derived Glycoproteins Exhibit Marked Differences in Susceptibility to Serum Neutralizing Antibodies: Genetic Subtype Defines Antigenic but Not Neutralization Serotype
  71. Acute Hepatitis C Virus Infection: A Dynamic—and Challenging—Concept
  72. A case of hepatitis C virus transmission acquired through sharing a haemodialysis machine
  73. Variation in the biological properties of HIV-1 R5 envelopes: implications of envelope structure, transmission and pathogenesis
  74. Variation in HIV-1 R5 macrophage-tropism correlates with sensitivity to reagents that block envelope: CD4 interactions but not with sensitivity to other entry inhibitors
  75. Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33
  76. Cross-genotype characterization of genetic diversity and molecular adaptation in hepatitis C virus envelope glycoprotein genes
  77. Identification of Conserved Residues in the E2 Envelope Glycoprotein of the Hepatitis C Virus That Are Critical for CD81 Binding
  78. Non-Macrophage-Tropic Human Immunodeficiency Virus Type 1 R5 Envelopes Predominate in Blood, Lymph Nodes, and Semen: Implications for Transmission and Pathogenesis
  79. Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33
  80. Evolutionary dynamics of hepatitis C virus envelope genes during chronic infection